evipedia.ai
← Back

PDE5 Inhibitors for Health & Longevity

Evidence Review created on 09/25/2026 using AI4L / Opus 5.5

Also known as: Phosphodiesterase Type 5 Inhibitors, Phosphodiesterase-5 Inhibitors, PDE-5 Inhibitors, PDE5i, Sildenafil, Viagra, Revatio, Tadalafil, Cialis, Adcirca, Vardenafil, Levitra, Staxyn, Avanafil, Stendra, Spedra, Udenafil, Zydena, Mirodenafil

Motivation

Phosphodiesterase type 5 inhibitors (PDE5 inhibitors) are a class of prescription oral medications, including sildenafil (Viagra) and tadalafil (Cialis), that help blood vessels relax by preserving a chemical signal the body already uses to widen arteries. Best known for treating erectile problems, they interest health-focused adults because they act on the inner lining of blood vessels, the same tissue whose decline drives heart disease.

Sildenafil began as a heart drug for chest pain before its effect on erections was noticed by chance. Decades later, large health-record studies have linked regular use to fewer heart attacks, longer survival and less Alzheimer’s disease, although such studies cannot separate the effect of the drug from the healthier habits and circumstances of the men who take it.

This review examines what the evidence shows for and against using these drugs as a health and longevity tool: the established benefits, the heart and brain signals, the known and disputed risks, how they are dosed and monitored, and where the evidence remains incomplete.

Benefits - Risks - Protocol - Conclusion

This section lists expert podcasts, articles and evidence summaries that discuss PDE5 inhibitors in depth.

  • #260 ‒ Men’s Sexual Health: why it matters, what can go wrong, and how to fix it – Mohit Khera, M.D., M.B.A., M.P.H. - Peter Attia

    Urologist Mohit Khera explains how sildenafil and tadalafil work, the history of erectile dysfunction drugs, how prescribing changes with age, and why erectile problems signal cardiovascular disease.

  • Dr. Rena Malik: Improving Sexual & Urological Health in Males and Females - Andrew Huberman

    Urologist Rena Malik discusses Viagra and Cialis for erectile dysfunction, daily tadalafil for prostate-related urinary symptoms, and priapism (a prolonged, painful erection), in clearly timestamped segments.

  • Erectile Dysfunction - Shayna Sandhaus

    Life Extension’s protocol explains how sildenafil, vardenafil and tadalafil inhibit the PDE5 enzyme and places them within an integrative strategy for vascular risk, hormones and lifestyle.

  • Viagra Identified as a Candidate Drug for Alzheimer’s - Arkadi Mazin

    Explains the computer-based gene-network and insurance-claims analysis that linked sildenafil to lower Alzheimer’s risk, and why that association does not establish causation.

  • PDE5 Inhibitors - Alzheimer’s Drug Discovery Foundation

    A brain-health evidence summary rating the potential benefit and safety of tadalafil, sildenafil and vardenafil, covering cerebral blood flow trials, observational dementia data and contraindication with nitrates (heart drugs that release nitric oxide).

Rhonda Patrick (FoundMyFitness) and Chris Kresser offer no overview of PDE5 inhibitors: FoundMyFitness has only a brief news item on Viagra in retinitis pigmentosa (inherited retinal degeneration), and Kresser mentions Viagra only in passing in two podcast episodes.

Grokipedia

PDE5 inhibitor

An encyclopedic overview of the drug class covering the nitric oxide signalling mechanism, development history, approved and off-label indications, comparative half-lives and response rates across agents.

Examine

No Examine article on PDE5 inhibitors exists. Examine.com does not typically cover prescription medications, and searches for sildenafil, tadalafil and PDE5 returned no results.

ConsumerLab

Is it safe to take arginine, or other supplements for sexual enhancement, while taking Viagra or Cialis?

Tod Cooperman reviews interactions of sildenafil and tadalafil with arginine, horny goat weed, St. John’s wort, grapefruit and pomegranate juice, and with supplements adulterated with these drugs.

Systematic Reviews

These five systematic reviews and meta-analyses cover efficacy, cardiovascular, dementia and cancer outcomes; most underlying erectile dysfunction and pulmonary hypertension (high blood pressure in the lung arteries) trials were sponsored by the drugs’ manufacturers (Pfizer, Eli Lilly, Bayer).

Mechanism of Action

Sexual arousal and blood flow along artery walls trigger release of nitric oxide (NO, a gas that signals blood vessels to relax) from nerve endings and the endothelium (the inner lining of blood vessels). NO activates soluble guanylate cyclase (an enzyme producing the messenger cyclic guanosine monophosphate, cGMP), and cGMP relaxes smooth muscle, widening arteries. PDE5 (phosphodiesterase type 5, the enzyme that breaks down cGMP) ends the signal. PDE5 inhibitors block this enzyme, so cGMP persists wherever NO is already released; they amplify the body’s own signal, which is why sexual stimulation is still required.

PDE5 is concentrated in penile erectile tissue, lung arteries, vascular smooth muscle, platelets, bladder and prostate, explaining effects on erections, blood pressure and urinary symptoms.

Key pharmacological properties:

  • Half-life: sildenafil 3–5 hours, vardenafil 4–5 hours, avanafil about 5 hours, tadalafil about 17.5 hours.
  • Selectivity: sildenafil and vardenafil partly inhibit PDE6 (the retinal enzyme for light signalling), causing blue-tinged vision; tadalafil partly inhibits PDE11 (a related enzyme in skeletal muscle that breaks down cGMP and cAMP, another cell messenger), linked to back pain.
  • Metabolism: all agents are cleared mainly by CYP3A4 (the main liver and gut drug-metabolizing enzyme); sildenafil also uses CYP2C9 (a second liver drug-metabolizing enzyme).
  • Distribution: mostly bound to blood proteins; tadalafil crosses the blood–brain barrier in mice (García-Barroso et al., 2013).

Competing interpretations exist: sustained cGMP signalling may protect heart muscle and arteries, yet it may aid invasion by some melanoma cells, underpinning the disputed cancer signal.

Historical Context & Evolution

Pfizer chemists in Sandwich, England, synthesized sildenafil (compound UK-92,480) around 1989 as a treatment for angina (chest pain from reduced heart blood flow). Early 1990s trials showed little benefit for angina but frequent erections, and the program pivoted. The US Food and Drug Administration (FDA) approved Viagra for erectile dysfunction (ED, persistent inability to achieve or maintain an erection) in 1998; vardenafil and tadalafil followed in 2003 and avanafil in 2012.

Early reports of cardiac deaths raised fears that the drug harmed the heart. Pooled analysis of largely Pfizer-sponsored trials found no excess of serious cardiovascular events or deaths (Fink et al., 2002), and attention shifted toward possible vascular benefits. Sildenafil (Revatio, 2005) and tadalafil (Adcirca, 2009) were approved for pulmonary arterial hypertension (PAH, high blood pressure in the lung arteries), and daily tadalafil for urinary symptoms of benign prostatic hyperplasia (BPH, non-cancerous prostate enlargement) in 2011.

Interest in health optimization grew from three developments: mouse work showing sildenafil prevents and reverses cardiac hypertrophy (heart-muscle thickening) (Takimoto et al., 2005), Swedish registry data associating use with lower mortality after heart attack (Andersson et al., 2017), and an insurance-claims analysis linking sildenafil to lower Alzheimer’s risk (Fang et al., 2021). Generic sildenafil (2017) and tadalafil (2018) then made daily use inexpensive. None of these signals has been tested in a longevity-focused randomized trial, and a Medicare analysis found no dementia benefit (Desai et al., 2022), so the question remains open in both directions.

Expected Benefits

High 🟩 🟩 🟩

Improved Erectile Function

PDE5 inhibitors restore erections in men with ED of vascular, diabetic, neurological or psychological origin by amplifying the NO signal in penile arteries. A meta-analysis of 27 randomized trials of sildenafil (Fink et al., 2002) and a network meta-analysis of 82 trials across agents (Chen et al., 2015) confirm efficacy for every agent; most underlying trials were sponsored by the manufacturers (Pfizer, Eli Lilly, Bayer). Response is weaker after prostate surgery and in poorly controlled diabetes. For health-focused men, preserved sexual function supports quality of life and relationships.

Magnitude: Successful intercourse attempts 57% with sildenafil vs 21% with placebo; 83% vs 45% of men had at least one success (Fink et al., 2002).

Relief of Enlarged-Prostate Urinary Symptoms

Daily tadalafil reduces lower urinary tract symptoms (LUTS: weak stream, urgency, night-time urination) caused by BPH, likely by relaxing smooth muscle and improving blood flow in the bladder neck and prostate. A meta-analysis of eight randomized trials (Dong et al., 2013) found consistent symptom improvement with simultaneous erectile benefit and no increase in serious adverse events; the underlying trials were largely sponsored by tadalafil’s manufacturer, Eli Lilly. For men in midlife and beyond, one medication addresses two common age-related complaints.

Magnitude: International Prostate Symptom Score (IPSS, a validated 0–35 symptom scale) improved by 2.19 points and International Index of Erectile Function (IIEF, a validated erectile-function questionnaire) by 4.66 points vs placebo (Dong et al., 2013).

Better Exercise Capacity and Survival in Pulmonary Arterial Hypertension

In PAH, PDE5 inhibitors dilate lung arteries and slow disease progression. A Cochrane review of 36 randomized trials (Barnes et al., 2019) rated gains in walking distance, functional class and short-term survival as high-certainty for sildenafil, tadalafil and vardenafil. Benefit was not shown for pulmonary hypertension caused by lung disease or chronic blood clots. PAH is rare, so this benefit matters mainly to affected individuals, but it demonstrates a hard survival effect of the class.

Magnitude: 48 m further on the six-minute walk test and 22% lower mortality over about 14 weeks; number needed to treat (NNT, patients treated to prevent one death) of 32 (Barnes et al., 2019).

Fewer Raynaud’s Attacks

Raynaud’s phenomenon (episodic spasm of finger arteries causing white, painful fingers in the cold), when secondary to conditions such as systemic sclerosis (an autoimmune disease that hardens skin and blood vessels), responds to PDE5-driven vasodilation. A meta-analysis of six double-blind randomized trials (Roustit et al., 2013) found significant but moderate reductions in attack frequency, duration and severity. Evidence for primary Raynaud’s without underlying disease is thinner.

Magnitude: 0.49 fewer attacks per day, 14.6 minutes less attack time per day, and a 0.46-point better Raynaud’s Condition Score vs placebo (Roustit et al., 2013).

Lower Blood Pressure and Improved Vascular Function

Continuous PDE5 inhibition modestly lowers blood pressure and improves measures of arterial health through sustained smooth-muscle relaxation and endothelial effects. A meta-analysis of 63 randomized trials with 3,242 participants (Zhang et al., 2025) found lower blood pressure, reduced arterial stiffness and carotid wall thickness, and better flow-mediated dilation (FMD, an ultrasound test of artery-lining function). The effect is small but relevant to cumulative cardiovascular risk over decades.

Magnitude: Systolic blood pressure −2.80 mmHg and diastolic −1.80 mmHg; FMD +2.47 percentage points vs placebo (Zhang et al., 2025).

Heart Failure Exercise Capacity

In heart failure with reduced ejection fraction (HFrEF, a weakened pump), PDE5 inhibitors lower lung-artery pressure and ease the load on the heart. A meta-analysis of small randomized trials (De Vecchis et al., 2017) found better exercise capacity, walking distance and pumping strength, plus fewer deaths and hospitalizations. In heart failure with preserved ejection fraction (HFpEF, a stiff heart), the RELAX trial found no benefit (Redfield et al., 2013), so the effect is confined to weakened hearts.

Magnitude: Peak oxygen uptake (maximal aerobic capacity during exercise) +3.76 mL/kg/min and six-minute walk distance +22.7 m in HFrEF trials (De Vecchis et al., 2017); 0.01 mL/kg/min difference in RELAX (Redfield et al., 2013).

Medium 🟩 🟩

Fewer Cardiovascular Events and Lower All-Cause Mortality

Men using PDE5 inhibitors have fewer heart attacks, strokes and deaths in large cohort studies, consistent with the vascular effects above. A meta-analysis of 16 cohort studies with 1.26 million men (Soulaidopoulos et al., 2024) and publicly funded Swedish registry data after heart attack (Andersson et al., 2017) show dose-dependent associations. Users tend to be healthier, wealthier and more sexually active than non-users, so healthy-user bias may explain part of the effect; no randomized trial has tested these outcomes.

Magnitude: Major adverse cardiovascular events (MACE: heart attack, stroke or cardiovascular death) relative risk (RR, risk in users divided by risk in non-users) 0.78, 95% confidence interval (CI, range likely to contain the true value) 0.69–0.89; all-cause mortality RR 0.70 (CI 0.56–0.87) (Soulaidopoulos et al., 2024).

Sexual Function in Women with Antidepressant-Associated Dysfunction

Selective serotonin reuptake inhibitors (SSRIs, a common antidepressant class such as sertraline) often impair arousal and orgasm. In a single randomized trial in 98 premenopausal women whose depression was in remission (Nurnberg et al., 2008), sildenafil reduced adverse sexual effects without worsening mood. Data in postmenopausal women and in women not taking antidepressants are limited and inconsistent.

Magnitude: Clinical Global Impression sexual function score 1.9 with sildenafil vs 1.1 with placebo, a difference of 0.8 (CI 0.6–1.0) (Nurnberg et al., 2008).

Low 🟩

Lower Alzheimer’s Disease Risk ⚠️ Conflicted

A meta-analysis of observational studies (Abouelmagd et al., 2024) and a UK cohort (Adesuyan et al., 2024) link use to lower Alzheimer’s incidence, but a Medicare cohort compared with another drug’s users found none (Desai et al., 2022). Net reading: confounding (user–non-user differences) likely explains much of the signal.

Magnitude: Pooled hazard ratio (HR, relative rate of disease over time) 0.53 (CI 0.32–0.86) in the meta-analysis vs HR 0.99 (CI 0.69–1.43) in the Medicare cohort.

Improved Insulin Sensitivity

A three-month randomized trial in 42 overweight adults with prediabetes (Ramirez et al., 2015) found sildenafil 25 mg three times daily improved insulin sensitivity, measured with a glucose clamp (a controlled glucose infusion test), and lowered urine albumin. The trial was small and used an indirect metabolic measure.

Magnitude: Insulin sensitivity index 1.84 units higher than placebo (CI 0.01–3.67), a borderline result (Ramirez et al., 2015).

Sperm Motility in Infertile Men ⭕️ Not Central to Health & Longevity

A meta-analysis of 11 studies (Tan et al., 2017) found modestly better sperm motility and shape in infertile but not fertile men. This bears on male fertility rather than health or lifespan.

Magnitude: Motile sperm +6.89 and normally shaped sperm +12.15 percentage points in infertile men (Tan et al., 2017).

Speculative 🟨

Increased Brain Blood Flow in Small Vessel Disease

In small vessel disease (damage to tiny brain arteries), the OxHARP trial (Webb et al., 2024) found sildenafil raised deep-brain blood flow and vessel responsiveness, both unvalidated markers. Whether this slows vascular dementia is untested.

Browning of White Fat

Sildenafil turned white fat heat-producing in mice (Mitschke et al., 2013) and raised fat-tissue UCP1 (a heat-generating protein) in 16 overweight men (Li et al., 2018). Effects on weight or metabolic health are unmeasured.

Benefit-Modifying Factors

  • Genetic polymorphisms: Variants in NOS3 (the gene for endothelial nitric oxide synthase, which produces vascular NO) and GNB3 (a gene for a cell-signalling G-protein subunit) have been associated with weaker sildenafil response in small studies; no genotype-guided prescribing exists.
  • Baseline testosterone: Men with testosterone below about 300 ng/dL respond less, because testosterone supports penile NO production; correcting deficiency can restore response in non-responders.
  • Baseline glycemia and vascular health: Higher HbA1c (glycated hemoglobin, average blood sugar over three months) and advanced atherosclerosis reduce erectile response, because NO production itself is impaired.
  • Sex: Nearly all erectile, urinary and cardiovascular-outcome data come from men; in women, benefit is shown mainly for PAH and antidepressant-associated sexual dysfunction.
  • Pre-existing conditions: Response is lower after prostate-removal surgery with nerve damage and in severe diabetes; vascular benefits appear larger in men with coronary disease or HFrEF than in healthy men.
  • Age: Efficacy persists beyond 65, although absolute response declines with age-related vascular and nerve changes; older users carry more cardiovascular risk for any vascular benefit to act on, but also reach higher drug levels.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Headache, Flushing and Nasal Congestion

Dilation of cranial, facial and nasal blood vessels causes the class’s most common adverse events. Pooled sildenafil trials report flushing in 12% and headache in 11% of men (Fink et al., 2002), and a Cochrane review confirms higher headache and flushing rates across agents (Barnes et al., 2019). Effects are dose-related, usually mild, and often fade with continued use.

Magnitude: Headache odds ratio (OR, odds of the event with the drug divided by odds with placebo) 1.97 and flushing OR 4.12 vs placebo (Barnes et al., 2019).

Dyspepsia and Reflux

Relaxation of the lower esophageal sphincter (the muscle ring that keeps stomach acid out of the esophagus) causes dyspepsia (indigestion) and heartburn. Dyspepsia affected 5% of sildenafil users in pooled trials (Fink et al., 2002), and gastrointestinal upset exceeded placebo across agents in the Cochrane review (Barnes et al., 2019). Symptoms are mild and dose-related.

Magnitude: Dyspepsia in 5% of sildenafil users; gastrointestinal upset OR 1.63 vs placebo (Barnes et al., 2019).

Back Pain and Muscle Aches

Myalgia (muscle aches) and back pain occur mainly with tadalafil, possibly through PDE11 inhibition in skeletal muscle. The Cochrane review found muscle and joint pain more than twice as likely as with placebo (Barnes et al., 2019). Symptoms typically begin 12–24 hours after a dose and resolve within about two days.

Magnitude: Muscle aches and joint pains OR 2.52 (CI 1.59–3.99) vs placebo (Barnes et al., 2019).

Symptomatic Hypotension with Nitrates or Alpha-Blockers

PDE5 inhibitors amplify blood-pressure lowering by nitrates (drugs that release NO to widen coronary arteries) and alpha-blockers (drugs relaxing prostate and vessel muscle). In randomized crossover trials, largely manufacturer-sponsored, sildenafil with isosorbide mononitrate dropped standing pressure far more than nitrate alone (Webb et al., 2000); the tadalafil–nitroglycerin interaction lasted 24 but not 48 hours (Kloner et al., 2003); tadalafil augmented doxazosin (Kloner et al., 2004).

Magnitude: Maximum standing fall −52/−29 mmHg with sildenafil plus isosorbide mononitrate vs −25/−15 mmHg with nitrate alone (Webb et al., 2000); standing systolic pressure below 85 mmHg in 28% with tadalafil plus doxazosin vs 6% with placebo plus doxazosin (Kloner et al., 2004).

Transient Visual Disturbances

Cross-inhibition of retinal PDE6 causes temporary blue-tinged vision, light sensitivity or blurring, mainly with sildenafil and vardenafil at higher doses. Pooled trials report visual disturbances in 3% of sildenafil users (Fink et al., 2002), and abnormal vision is among the most frequently reported reactions in the World Health Organization adverse-event reporting database (Lui et al., 2023). Effects resolve within hours.

Magnitude: Visual disturbances in 3% of sildenafil users in pooled trials; abnormal vision in 8.4% of spontaneous adverse-event reports (Lui et al., 2023).

Medium 🟥 🟥

Sudden Sensorineural Hearing Loss

Sudden hearing loss from inner-ear damage, sometimes with tinnitus (ringing in the ears) or vertigo (spinning dizziness), carries an FDA label warning. A claims-based cohort of 377,722 users (Liu et al., 2018) found a small but significant increase, and a systematic review of case reports (Pinkus et al., 2026) found full recovery in only a minority of cases with follow-up. Absolute risk is very low.

Magnitude: HR 1.25 (CI 1.01–1.55) for current use, about 2 extra cases per 10,000 person-years (10,000 people followed for one year) (Liu et al., 2018).

Low 🟥

Nonarteritic Anterior Ischemic Optic Neuropathy ⚠️ Conflicted

NAION (sudden, painless vision loss from reduced optic-nerve blood flow) was twice as likely within five half-lives of dosing in a Pfizer-funded self-comparison study (Campbell et al., 2015), while a meta-analysis found no significant association (Penedones et al., 2020). Net reading: a rare, possible trigger in susceptible eyes.

Magnitude: OR 2.15 (CI 1.06–4.34), about 3 extra cases per 100,000 men over 50 per year with weekly use (Campbell et al., 2015); pooled OR 1.16 (CI 0.89–1.52).

Melanoma ⚠️ Conflicted

Meta-analyses find slightly more melanoma among users (Kreuz et al., 2025), but the excess lacked dose-response, clustered in early-stage tumors and extended to basal cell cancer (a common, rarely fatal skin cancer), suggesting sun-exposure confounding (Loeb et al., 2017). Net reading: causation is unlikely but not excluded.

Magnitude: Pooled HR 1.10 (CI 1.03–1.17) (Kreuz et al., 2025); RR 1.11 (CI 1.02–1.22) (Loeb et al., 2017).

Priapism

Priapism (an erection lasting over four hours, an emergency that can permanently damage erectile tissue) is reported with all agents. Adverse-event reporting signals concentrate in young users (Abbasi et al., 2024), and published drug-induced cases rarely involve PDE5 inhibitors (Rezaee & Gross, 2020).

Magnitude: Priapism made up 0.41% of PDE5-inhibitor adverse-event reports, with a reporting odds ratio (how much more often an event is reported with a drug than with comparison drugs) of 1.38 (CI 1.24–1.54), rising to 4.57 in users under 18 (Abbasi et al., 2024); no study reports an incidence rate among users.

Speculative 🟨

Retinal Harm in Carriers of Retinal Degeneration Mutations

People with retinitis pigmentosa (inherited retinal degeneration, sometimes from PDE6 mutations) were excluded from trials. Harm from long-term PDE6 cross-inhibition is proposed on mechanistic grounds only, without controlled data.

Risk-Modifying Factors

  • Genetic polymorphisms: CYP3A4 and CYP3A5 variants (genes for the main PDE5-inhibitor-clearing enzymes) alter drug exposure, and PDE6 mutations underlying retinitis pigmentosa may heighten retinal vulnerability; no routine pharmacogenetic testing is established.
  • Baseline blood pressure: Resting pressure below 90/50 mmHg or orthostatic hypotension (a blood-pressure drop on standing) raises fainting risk; uncontrolled pressure above 170/110 mmHg is a labeled caution.
  • Optic disc anatomy: A small, crowded optic disc, common in NAION patients, and prior NAION in one eye raise concern that further use could trigger optic-nerve damage.
  • Sex: Women are underrepresented in safety data outside PAH; use in pregnancy is not established, and erectile-indication safety data are male-only.
  • Cardiovascular disease: Unstable angina, heart attack or stroke within six months, aortic stenosis (a narrowed heart valve) and conditions needing nitrates raise risk from hypotension and from the exertion of sexual activity.
  • Liver and kidney impairment: Severe liver impairment and creatinine clearance (a measure of kidney filtering) below 30 mL/min raise drug exposure; the tadalafil label excludes daily dosing below 30 mL/min.
  • Skin cancer history: Personal or family melanoma history makes the conflicted melanoma signal more relevant.
  • Age: Beyond 65, free sildenafil levels are about 40% higher, and orthostatic hypotension, multiple medications, NAION and hearing-loss risk all become more common.

Key Interactions & Contraindications

Prescription drugs

  • Organic nitrates and NO donors (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, nicorandil): Absolute contraindication; profound hypotension, fainting and heart ischemia. Nitrates are withheld for 24 hours after sildenafil or vardenafil and 48 hours after tadalafil.
  • Soluble guanylate cyclase stimulators (riociguat, vericiguat; drugs that directly raise cGMP): Contraindicated with riociguat, not recommended with vericiguat; additive cGMP rise causes severe hypotension. No safe spacing is defined.
  • Alpha-blockers (doxazosin, terazosin, alfuzosin, tamsulosin): Caution; orthostatic hypotension and dizziness. The PDE5 inhibitor starts at the lowest dose only once alpha-blocker therapy is stable; tamsulosin interacts least.
  • Strong CYP3A4 inhibitors (drugs blocking the main PDE5-inhibitor-clearing enzyme: ritonavir, ketoconazole, itraconazole, clarithromycin): Caution with dose caps; PDE5-inhibitor levels rise several-fold, increasing hypotension and priapism risk. Caps: sildenafil 25 mg per 48 hours with ritonavir; tadalafil 10 mg per 72 hours.
  • CYP3A4 inducers (drugs speeding up that enzyme: rifampin, carbamazepine, phenytoin): Monitor; lower PDE5-inhibitor levels and reduced efficacy. Dose adjustment may be needed.
  • Antihypertensives (blood-pressure drugs: amlodipine, losartan, lisinopril, chlorthalidone): Monitor; small additive fall in blood pressure. Standing blood pressure is checked after starting.
  • QT-prolonging antiarrhythmics (heart-rhythm drugs) with vardenafil (quinidine, procainamide, amiodarone, sotalol): Avoid; vardenafil modestly prolongs the QT interval (the heart’s electrical recovery time), raising arrhythmia risk. Another agent is preferred.

Over-the-counter medications and foods

  • Cimetidine (acid reducer): Monitor; raises sildenafil levels by about 56% via CYP3A4 inhibition. A lower starting dose offsets this.
  • Alkyl nitrite inhalants (“poppers”, amyl nitrite): Absolute contraindication; severe hypotension and collapse. No safe interval is defined.
  • Alcohol: Caution; heavy intake adds orthostatic hypotension, rapid heart rate and headache, and itself impairs erections. Moderate intake has little effect.
  • Grapefruit juice: Monitor; inhibits intestinal CYP3A4, raising sildenafil exposure. Avoiding large amounts around dosing prevents stronger side effects.

Supplements

  • L-arginine and L-citrulline: Caution; additive NO supply can lower blood pressure further. Standing blood pressure is checked when combined.
  • Horny goat weed (Epimedium, icariin) and yohimbe: Caution; icariin is a weak PDE5 inhibitor with additive vasodilation, and yohimbe raises heart rate and blood pressure. Combination is avoided.
  • Sexual enhancement supplements: Caution; frequently adulterated with undeclared sildenafil or tadalafil, causing unintended double dosing and hidden nitrate risk. Avoided during PDE5-inhibitor use.
  • St. John’s wort: Monitor; CYP3A4 induction lowers PDE5-inhibitor levels and efficacy. Dose response is reassessed.
  • Blood-pressure-lowering supplements (beetroot nitrate, garlic, magnesium, hibiscus): Monitor; additive modest hypotension, especially with concentrated dietary nitrate. Doses are separated and standing blood pressure checked.

Other interventions

  • Penile injection therapy (alprostadil) or other erectile treatments: Caution; combining erectile treatments raises priapism risk. One treatment is used at a time unless supervised.
  • Sauna and hot-tub exposure: Monitor; heat-induced vasodilation adds to hypotension and dizziness. Hydration and rising slowly reduce fainting.

Populations who should avoid PDE5 Inhibitors:

  • People using any organic nitrate or nitrite inhalant, or riociguat
  • Resting hypotension (below 90/50 mmHg) or uncontrolled hypertension (above 170/110 mmHg)
  • Heart attack, stroke or life-threatening arrhythmia within the past 6 months
  • Unstable angina or angina during sexual intercourse
  • Advanced heart failure (New York Heart Association Class III–IV, symptoms with minimal exertion or at rest), where the exertion of sexual activity itself is unsafe
  • Severe aortic stenosis or hypertrophic obstructive cardiomyopathy (thickened heart muscle blocking outflow)
  • Severe liver impairment (Child-Pugh Class C, the most severe grade of a liver-disease scoring system)
  • Creatinine clearance below 30 mL/min (daily tadalafil)
  • Hereditary retinal degeneration, including retinitis pigmentosa
  • Prior NAION in either eye
  • Sickle cell disease with pulmonary hypertension (sildenafil increased vaso-occlusive crises, painful episodes of blood vessels blocked by sickled cells)
  • Pregnancy (erectile or longevity use)

Risk Mitigation Strategies

  • Nitrate-interval rule: Recording the time of the last dose (e.g., a wallet card) lets emergency staff withhold nitrates for 24 hours after sildenafil or vardenafil and 48 hours after tadalafil, preventing severe hypotension.
  • Low starting dose: Starting at sildenafil 25 mg or tadalafil 2.5 mg daily and increasing only after 2 weeks or 4–8 attempts reduces headache, flushing and hypotension.
  • Standing blood pressure checks: Measuring seated and standing blood pressure at baseline and 1–2 weeks after starting detects orthostatic hypotension (a fall of 20/10 mmHg or more on standing) before fainting occurs.
  • Alpha-blocker sequencing: Stabilizing on the alpha-blocker first, then adding the lowest PDE5-inhibitor dose, and spacing sildenafil 4 hours from the alpha-blocker limits additive hypotension.
  • Vision and hearing stop rule: Stopping immediately and seeking same-day evaluation for sudden vision or hearing loss limits permanent damage from NAION or sudden hearing loss.
  • Priapism action plan: Treating any erection lasting over 4 hours as an emergency, with urologic care within 6 hours, prevents permanent erectile tissue damage.
  • Interaction screening: Reviewing every new prescription, especially antibiotics (clarithromycin), antifungals and HIV drugs, applies CYP3A4 dose caps and prevents excess drug levels.
  • Reflux reduction: Taking the dose with water, staying upright for 30 minutes and avoiding late heavy meals reduces dyspepsia and heartburn.
  • Myalgia management: Hydration, dose reduction to tadalafil 2.5 mg, or switching to sildenafil reduces tadalafil-associated back pain and muscle aches.
  • Skin surveillance: Annual full-skin examination and daily sun protection of at least SPF 30 (sun protection factor) for users with melanoma risk factors address the conflicted melanoma signal.
  • Verified pharmacy sourcing: Buying only from licensed pharmacies prevents counterfeit products with wrong doses, contaminants or undeclared drugs.

Therapeutic Protocol

  • Daily low-dose tadalafil: 2.5–5 mg once daily, the labeled regimen for daily erectile use and BPH; discussed as a vascular-health option by urologist Mohit Khera on The Peter Attia Drive and offered by longevity telehealth clinics.
  • On-demand sildenafil: 25–100 mg (commonly 50 mg) 30–60 minutes before sexual activity, at most once daily; the original Pfizer-labeled approach and the most effective starting dose in network meta-analysis.
  • On-demand tadalafil: 10–20 mg at least 30 minutes before activity, at most once daily; the effect lasts up to 36 hours, favoring spontaneity.
  • Competing approaches: Conventional urology treats symptoms on demand, while integrative and longevity practitioners favor continuous low-dose tadalafil for endothelial effects; neither approach has outcome trials in healthy adults.
  • Pulmonary hypertension regimen (context): Sildenafil 20 mg three times daily or tadalafil 40 mg once daily under specialist care shows the higher continuous exposure that has been studied for safety.
  • Time of day: No study defines an optimal time. Evening dosing places peak headache or flushing during sleep; morning dosing avoids night-time reflux. Consistent timing matters most for daily use.
  • Half-life and food: Sildenafil (half-life 3–5 hours) is delayed about 1 hour by a high-fat meal; tadalafil (half-life about 17.5 hours) is unaffected by food and reaches steady state (stable blood levels) after about 5 daily doses.
  • Single vs split dosing: Tadalafil’s long half-life allows single daily dosing; sildenafil needs three daily doses for continuous effect, as used in pulmonary hypertension.
  • Genetic polymorphisms: No pharmacogenetic dosing rule exists; slow CYP3A4 or CYP3A5 metabolizers may reach higher levels, which favors the lowest starting dose.
  • Sex differences: Female dosing exists only for PAH, at the same doses as men; erectile-indication doses are male-specific, and sildenafil for women’s sexual dysfunction is off-label.
  • Age: Beyond 65, sildenafil starts at 25 mg because exposure is higher; tadalafil needs no age adjustment, but kidney function is checked first.
  • Baseline biomarkers: Low testosterone, poorly controlled HbA1c and low baseline blood pressure are addressed before dose escalation, because they blunt response or raise hypotension risk.
  • Pre-existing conditions: Creatinine clearance 30–50 mL/min limits on-demand tadalafil to 10 mg every 48 hours; mild-to-moderate liver impairment caps tadalafil at 10 mg; cardiac fitness for sexual activity is assessed first.

Discontinuation & Cycling

  • Lifelong or short-term: On-demand use is episodic; daily tadalafil for urinary or vascular goals is open-ended, and its benefits persist only while it is taken.
  • Withdrawal effects: None documented; stopping causes no rebound hypertension, dependence or withdrawal syndrome.
  • Tapering: Not required; both daily and on-demand use can stop abruptly.
  • Cycling: No evidence that cycling maintains efficacy; tolerance has not been shown in long-term extension studies of daily tadalafil.
  • Return of symptoms: Erectile and urinary symptoms return toward baseline within days to weeks of stopping daily tadalafil.
  • Stopping triggers: Sudden vision or hearing loss, a new nitrate prescription, chest pain needing emergency care, or a melanoma diagnosis prompt stopping.

Sourcing and Quality

  • Prescription status: Prescription-only in the US and most countries; the UK has permitted pharmacist sale of sildenafil 50 mg (Viagra Connect) since 2018.
  • FDA-approved generics: Generic sildenafil and tadalafil must be bioequivalent to brand products and meet US Pharmacopeia standards; established manufacturers include Teva, Aurobindo, Cipla and Camber.
  • Counterfeits: Websites selling without prescriptions frequently supply counterfeit tablets with wrong doses or contaminants; pharmacies are verified through FDA BeSafeRx or the National Association of Boards of Pharmacy “.pharmacy” domain.
  • Adulterated supplements: Supplements marketed for sexual enhancement often contain hidden sildenafil, tadalafil or unapproved analogues; FDA and ConsumerLab maintain recall lists.
  • Compounded formulations: Licensed compounding pharmacies produce under-the-tongue lozenges and combinations; these lack FDA approval and bioequivalence testing, so potency may vary between batches.
  • Formulations: Tablets, orally disintegrating vardenafil (Staxyn) and oral suspensions for pulmonary hypertension; orally disintegrating forms are not interchangeable milligram for milligram.
  • Third-party testing: Pharmacy-dispensed products are FDA-regulated, whereas products bought outside pharmacy channels have no independent verification, which third-party supplement seals do not replace.

Practical Considerations

  • Time to effect: Sildenafil acts within 30–60 minutes and tadalafil within 30–120 minutes; daily tadalafil reaches steady state in about 5 days, with urinary benefit in 1–4 weeks. Vascular effects, if real, would accrue over months to years.
  • Common pitfalls: Judging failure after one or two doses, taking sildenafil after a fatty meal, expecting effect without sexual stimulation, combining with “poppers” or unverified supplements, and buying from unlicensed websites.
  • Regulatory status: FDA-approved for ED, BPH symptoms (tadalafil) and PAH (sildenafil, tadalafil); use for cardiovascular prevention, dementia prevention or longevity is off-label.
  • Cost and accessibility: Generic tadalafil 5 mg and sildenafil cost well under US$1 per dose with discount programs; many insurers restrict erectile-indication coverage, while daily tadalafil for BPH is covered more often.
  • Payer and funding incentives: Because both drugs are generic, no manufacturer funds longevity trials, and insurers that classify them as lifestyle drugs have little incentive to fund prevention research, a structural reason the heart and dementia signals remain untested.

Interaction with Foundational Habits

  • Sleep: Indirect. Nasal congestion from vasodilation can worsen snoring and night-time breathing in untreated sleep apnea, and evening doses may shift headache into the night. Poor sleep lowers testosterone and erectile function, blunting response, so sleep quality supports benefit.
  • Nutrition: Direct and potentiating. High-fat meals delay sildenafil absorption by about an hour; grapefruit raises exposure. A Mediterranean-style diet improves endothelial function and erectile response, and dietary nitrate (beetroot, leafy greens) adds to NO supply, modestly deepening blood-pressure effects.
  • Exercise: Potentiating. Aerobic training increases endothelial NO production, adding to vascular benefit. Sildenafil does not enhance performance at sea level but lowers lung artery pressure at high altitude; dizziness can occur with strenuous exertion soon after dosing.
  • Stress management: Indirect. Performance anxiety raises sympathetic (fight-or-flight) tone, which constricts penile arteries and counteracts PDE5 inhibition; reliable drug response can reduce anticipatory anxiety. No direct effect on cortisol is documented; mindfulness or cognitive behavioral therapy complements treatment.

Monitoring Protocol & Defining Success

Before starting, baseline testing establishes fitness for sexual activity, excludes contraindications and records starting values: seated and standing blood pressure, a lipid panel with apolipoprotein B (ApoB, the protein carried by each artery-clogging lipoprotein particle), HbA1c, morning total and free testosterone, kidney and liver function, and validated symptom scores (IIEF-5 for erections, IPSS for urinary symptoms). A resting electrocardiogram and an eye examination are added when cardiovascular or optic-nerve risk factors exist.

Ongoing monitoring follows a set cadence: blood pressure at 1–2 weeks and after any dose change; symptom scores at 4–12 weeks; then blood pressure, lipids, HbA1c and kidney function every 6–12 months, plus an annual skin examination for those with melanoma risk factors. Any sudden change in vision or hearing prompts immediate evaluation rather than waiting for scheduled testing.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure (seated and standing) Below 120/80 mmHg seated; standing drop under 20/10 mmHg Hypotension risk; vascular effect Conventional hypertension threshold 130/80 mmHg; measure after 5 minutes seated, then 1–3 minutes standing
ApoB Below 80 mg/dL (below 60 mg/dL at high risk) Atherosclerosis driving ED Conventional labs flag only above about 130 mg/dL; fasting not required; pair once with lipoprotein(a) (an inherited cholesterol-carrying particle)
HbA1c 4.8–5.4% Sugar damage to vessels and nerves Conventional normal below 5.7%; no fasting needed
Total testosterone (morning) 500–900 ng/dL Low levels blunt response Conventional lower limit about 264–300 ng/dL; draw 7–10 a.m. fasting; pair with free testosterone and SHBG (sex hormone-binding globulin)
eGFR Above 90 mL/min/1.73 m² Guides tadalafil dosing eGFR = estimated glomerular filtration rate (kidney filtering capacity); conventional threshold about 60; dose limits below 50 and 30 mL/min; pair with cystatin C (a second kidney-filtration marker)
ALT Below 25 U/L Liver clears all agents ALT = alanine aminotransferase (liver enzyme); conventional upper limit about 40–55 U/L
hs-CRP Below 1.0 mg/L Vascular inflammation hs-CRP = high-sensitivity C-reactive protein (inflammation marker); conventional cutoff 3.0 mg/L; repeat if above 10 mg/L
IIEF-5 score 22–25 Erectile response Five-item version of the IIEF questionnaire; 21 or below indicates ED; reassess at 4–12 weeks
IPSS 0–7 Urinary benefit of daily tadalafil Validated 0–35 scale; a fall of 3 or more points is clinically meaningful
Eye examination (acuity, optic disc) No established target; track change from own baseline Optic-nerve risk Most useful with a crowded optic disc, prior NAION or diabetes

Qualitative markers:

  • Erection firmness, reliability and confidence during sexual activity
  • Frequency of spontaneous morning erections
  • Night-time urination frequency and urinary stream strength
  • Exercise tolerance and energy during daily activities
  • Side-effect diary: headache, flushing, reflux, back pain, dizziness on standing
  • Any change in color vision, visual field or hearing
  • Sexual and relationship satisfaction

Emerging Research

  • Tadalafil in early Alzheimer’s disease: An Imperial College London phase 2 placebo-controlled trial (NCT07172815) plans one year of tadalafil in 244 amyloid-positive people (with the Alzheimer’s-linked amyloid protein confirmed in the brain) with mild cognitive impairment or early Alzheimer’s; the primary endpoint is safety, with cognition secondary. Not yet recruiting.
  • Tadalafil for cerebral small vessel disease: The ETLAS-2 phase 2 trial (NCT05173896), still in follow-up, reported primary results (Ölmestig et al., 2025): in 76 patients given daily tadalafil 20 mg or placebo for three months, adherence missed its target, adverse events doubled and cognition did not improve.
  • Tadalafil and mirabegron in prediabetes: A phase 4 trial (NCT05051436) in 96 obese, insulin-resistant adults tests whether tadalafil alone or with mirabegron (a beta-3 agonist that activates brown fat) improves 14-week glucose tolerance.
  • Brain perfusion after OxHARP: The completed OxHARP trial (NCT03855332; Webb et al., 2024) found sildenafil increased cerebral perfusion without reducing the heartbeat-driven pressure surges in brain arteries; the authors call for outcome trials in small vessel disease.
  • Confounding in dementia signals: Wu & Swardfager, 2024 argue that comparator choice and confounding by indication (distortion from the reasons people are prescribed a drug) inflate observational dementia benefits, and Desai et al., 2022 found no association, findings that could weaken the case.
  • Cardiovascular outcome trials: Pooled cohort data (Soulaidopoulos et al., 2024) call for randomized trials of long-term PDE5 inhibition for cardiovascular events; none in healthy adults is registered, leaving the mortality signal untested in either direction.
  • Cardiac remodeling: A meta-analysis of 24 randomized trials (Giannetta et al., 2014) found continuous PDE5 inhibition reduced heart-muscle mass and improved pumping in hypertrophied hearts; confirmation in hard outcomes could strengthen the cardiovascular case.
  • Melanoma causality: The updated pooling (Kreuz et al., 2025) keeps the melanoma question open; studies adjusting for sun exposure and testing dose-response could confirm or dismiss the risk.

Conclusion

These drugs are inexpensive, well-studied oral medications that strengthen the body’s own signal for relaxing blood vessels. Their benefits for erections, urinary symptoms of an enlarged prostate, high blood pressure in the lungs and cold-triggered finger spasms rest on repeated controlled trials, and they slightly lower blood pressure and improve artery function. For health-focused adults, the more intriguing claims of fewer heart attacks, longer survival and protection against Alzheimer’s disease come from large health-record studies. These are consistent for heart outcomes but conflicting for dementia, and the men who take these drugs tend to be healthier to begin with, so any true effect is of unknown size.

The risks are well mapped. Headache, flushing, indigestion, muscle aches and brief color changes in vision are common and usually mild. The most dangerous interaction, a severe drop in blood pressure with nitroglycerin-type heart medications or “poppers”, is predictable and avoidable. Sudden hearing loss is a rare but credible concern, while links to a form of sudden vision loss and to skin cancer remain disputed.

Much of the evidence on effectiveness and safety was produced or paid for by the companies that make these drugs. As cheap generics, they now give neither those companies nor insurers much financial reason to pay for long-term prevention studies, so the heart and brain questions remain open. For this audience, daily low-dose use sits between a proven treatment for specific symptoms and a plausible but unproven tool against blood-vessel aging.

Top - Benefits - Risks - Protocol